Abstracts tagged "immunology"

Abstract Number: 2004 • ACR Convergence 2024
Rheumatic Complications Post-CAR-T Cell Therapy. Experience of a Single Center
Jose Alfredo Gomez-Puerta¹, Ana Monegal¹, Andrés Ponce², Pilar Peris³, Nuria Martínez⁴, Valentin Ortiz-Maldonado⁴, Ana Triguero⁴, Carlos Fernández de larrea⁴, Julio Delgado⁴, Raimon Sanmartí Sala¹ and Manuel Juan⁵, ¹Rheumatology Department, Hospital Clinic of Barcelona, Barcelona, Spain, ²Rheumatology Department, Hospital Clínic of Barcelona, Barcelona, Spain, ³Rheumatology Department, Hospital Clínic de Barcelona, Barcelona, Spain, ⁴Haematology Department, Hospital Clinic of Barcelona, Barcelona, Spain, ⁵Immunology Department, Hospital Clinic of Barcelona, Barcelona, Spain
Background/Purpose: CAR-T cell therapy is a promising treatment for a range of systemic autoimmune diseases such as systemic lupus erythematosus, systemic sclerosis, and antisynthetase syndrome,…
Abstract Number: 2662 • ACR Convergence 2024
In Vivo Generation of B Cell Depleting CAR T Cell Therapies for Treatment of Autoimmune Diseases
Laurie Beitz¹, Maura Parker¹, Justin Ulrich-Lewis¹, Kristen Mittelsteadt¹, Rebecca Gottschalk¹, Chris Nicolai¹, Jim Qin¹, Andrew Scharenberg¹, Ryan Larson¹, Byoung Ryu¹, Eric Cavanaugh², Weiliang Tang¹, Seungjin Shin¹, Kelsey Lynch¹ and Hans-Peter Kiem², ¹Umoja Biopharma, Seattle, WA, ²Fred Hutch Cancer Research Center, Seattle, WA
Background/Purpose: CAR T cell therapy promises to revolutionize the treatment of hematologic malignancies, and more recently has generated early data that it may afford long…
Abstract Number: 0019 • ACR Convergence 2024
A Novel Product Candidate (CPTX2309) for In Vivo mRNA Engineering of Anti-CD19 CAR T Cells Utilizing Novel CD8-Targeted Lipid Nanoparticles
Theresa Hunter¹, Ferran Soldevila¹, Yan Zhang¹, Brittany Ross¹, Daiki Matsuda¹, Yanjie Bao¹, John Li¹, Michelle Nguyen¹, Matthew Butcher¹, MIchael Pica¹, Claudia Fernandez¹, James Vestal¹, Goutam Mondal¹, Yi Kuo¹, Jeffrey Chen¹, Josephine Nguyen², Young Yoon Choi², Diana Galvan¹, Duy Nguyen¹, Donald Jhung², Stuart Sievers¹, Steven Tanis¹, Cory Bentley², Michael Rosenzweig¹, Priya Karmali¹, Adrian Bot¹, Haig Aghajanian¹ and Gregor Adams¹, ¹Capstan Therapeutics, San Diego, CA, ²Capstan Therapeutics, San Diego
Background/Purpose: Ex vivo chimeric antigen receptor (CAR) T cell therapies have revolutionized cancer treatment and are demonstrating clinical efficacy in various autoimmune disease indications. Despite…
Abstract Number: 0782 • ACR Convergence 2024
30-Color Full Spectrum Flow Cytometry Identifies Sex Differences in the Circulating Immune Landscape of Systemic Sclerosis
Sylvia Posso¹, Jane Buckner², Montserrat Anguera³ and Nikhil Jiwrajka⁴, ¹Benaroya Research Institute at Virginia Mason, Seattle, WA, ²Benaroya Research Institute, Seattle, WA, ³University of Pennsylvania, Philadelphia, PA, ⁴Hospital of the University of Pennsylvania, Philadelphia, PA
Background/Purpose: Systemic sclerosis (SSc) is a heavily female-biased systemic autoimmune disease associated with significant morbidity and mortality due to fibrosis of the skin and vital…
Abstract Number: 1532 • ACR Convergence 2024
Not yet on Track: Retrospective Chart Analysis Reveals Physician’s Treatment Approaches in SLE Fall Short of New EULAR Guidance
Maxine Yarnall¹, Ryan Rex² and Sawyer May¹, ¹Spherix Global Insights, Exton, PA, ²Spherix Global Insights, Chester Springs, PA
Background/Purpose: In October 2023, EULAR released updated recommendations for the management of SLE2. Notably, since the previous guidelines update in 2019, anifrolumab received approval for…
Abstract Number: 1844 • ACR Convergence 2024
Manufacturing of IMPT-514, a CD19/CD20 Bispecific CAR T Cell Product Candidate as a Potential Treatment of Patients with Autoimmune Diseases
Ethan BenDavid, Nathanael Joshua Bangayan, Orit Foord, Michael Weist, Melanie Munguia, Jessica Reyes and Jiajia Cui, ImmPACT Bio, West Hills, CA
Background/Purpose: Immunotherapies targeting antigens expressed on B cells are currently being explored as treatments for autoimmune disorders like antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV), idiopathic…
Abstract Number: 2052 • ACR Convergence 2024
Role of Scleroderma/myositis-related Autoantibodies Detected by Immunoblot to the Diagnosis of Systemic Autoimmune Rheumatic Diseases in 410 Patients from a Single Referral Center
Carmen Secada Gómez¹, Diana Prieto-Peña², Mónica Renuncio-García³, Juan Irure-Ventura⁴, Marcos Lopez-Hoyos⁵ and Ricardo Blanco-Alonso⁶, ¹Rheumatology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain, ²Division of Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL, Immunopathology group, Santander, Cantabria, Spain, ³Division of Immunology, Hospital Universitario Marqués de Valdecilla, Immunopathology Group, IDIVAL, Santander, Spain, ⁴Division of Immunology, Hospital Universitario Marqués de Valdecilla. Immunopathology group, IDIVAL, Santander, Cantabria, Spain, ⁵Division of Immunology, Hospital Universitario Marqués de Valdecilla. Immunopathology group, IDIVAL, Santander, Spain, ⁶Division of Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL, Immunopathology group, Santander, Spain
Background/Purpose: In clinical practice, immunoblot assays are being used more frequently as a diagnostic tool for systemic autoimmune rheumatic diseases (SARDs).Our aim was to evaluate the…
Abstract Number: 2667 • ACR Convergence 2024
Anti-Mi2 Autoantibodies in Dermatomyositis Patients Also Recognize Autoimmune Regulator (AIRE) Protein
Jon Musai¹, Sahana Jayaraman², katherine Pak³, Iago Pinal-Fernandez⁴, Sandra Muñoz-braceras⁵, Maria Casal-Dominguez⁶, Eric Cho⁵, Fa'alataitaua Fitisemanu⁵, jose milisenda⁷, Lisa Rider⁸, Adam Schiffenbauer³, Albert Selva-O’Callaghan⁹, Thomas E Lloyd¹⁰, Lisa Christopher-Stine¹¹, Peter Burbelo¹², Benjamin Larman¹¹ and Andrew Mammen¹³, ¹National Institute of Arthritis and Musculoskeletal and Skin Diseases, Bethesda, MD, ²Johns Hopkins University School of Medicine, Baltimore, MD, ³National Institutes of Health, Bethesda, MD, ⁴NIAMS/National Institutes of Health, Bethesda, MD, ⁵National Institute of Arthritis and Musculoskeletal and Skin Disease, Bethesda, MD, ⁶NIAMS, NIH, Bethesda, MD, ⁷Hospital Clinic de Barcelona, Barcelona, Spain, ⁸NIEHS, NIH, Garrett Park, MD, ⁹Systemic Autoimmune Disease Unit, Vall d’Hebron Institute of Research, Barcelona, Spain, ¹⁰Johns Hopkins University School of Medicine, Lutherville, MD, ¹¹Johns Hopkins University, Baltimore, MD, ¹²National Institute of Dental and Craniofacial Research, Bethesda, MD, ¹³NIH, Bethesda, MD
Background/Purpose: Many myositis patients have myositis-specific autoantibodies (MSA) that define unique clinical phenotypes. For instance, dermatomyositis (DM) patients with anti-Mi2 autoantibodies have weaker muscles, higher…
Abstract Number: L18 • ACR Convergence 2023
Immune-metabolic Heterogeneity and Clinical Implications in Primary Sjogren’s Syndrome Revealed by Molecular Classification of Salivary Glands
Xiaobing Wang¹, Jing Luo², Senhong Ying³, Jingwei Hong⁴, Hui Cheng⁴, Ping Wang⁴, Yanran He⁵, Wenjing Ye⁶, Xiaofang Zhu⁷, Chengwei Zhu⁸, Langxiong Yang², Zhongshan Li⁹, Suxian Lin¹⁰, Dan Chen⁷, Xin Wu¹¹, Zhengwei Xie¹², Jinyu Wu¹³ and Huji Xu¹, ¹Department of Rheumatology and Immunology, Changzheng Hospital, Naval Medical University, Shanghai, China, ²School of Medicine, Tsinghua University, Beijing, China, ³Precision Medicine Center, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, China, ⁴Department of Rheumatology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China, ⁵Committee on Cancer Biology, University of Chicago, Chicago, IL, ⁶Division of Rheumatology, Huashan Hospital, Fudan University, Shanghai, China, ⁷Rheumatology Department, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China, ⁸Department of Ultrasonography, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China, ⁹Wenzhou Medical University, Wenzhou, China, ¹⁰Rheumatology Department, Wenzhou People's Hospital, Wenzhou, China, ¹¹Department of Rheumatology and Immunology,Changzheng Hospital, Naval Medical University, Shanghai, China, ¹²Peking University International Cancer Institute, Health Science Center, Peking University, Beijing, China, ¹³Institute of Genomic Medicine, Key Laboratory of Laboratory Medicine, Ministry of Education, Wenzhou Medical University, Wenzhou, China
Background/Purpose: Primary Sjögren's syndrome (pSS) is a complex autoimmune disease with significant heterogeneity. Our study aimed to clarify the etiology and molecular variation of the…
Abstract Number: 0040 • ACR Convergence 2023
Non-canonical NF-κB Signalling Is Required for Extrathymic AIRE Expression and Immunoregulatory Molecules in Cells of the Dendritic Lineage
Guus van Laar¹, Leonie Huitema¹, Boy helder¹, Joanna Fergusson¹, Hergen Spits¹, Jan Piet van Hamburg¹ and Sander Tas², ¹Amsterdam University Medical Centers, Amsterdam, Netherlands, ²Amsterdam UMC, locatie AMC, Utrecht, Netherlands
Background/Purpose: The transcription factor Autoimmune Regulator (AIRE) is crucial for the establishment of central tolerance in the thymus. Recently, peripheral CD45+ extrathymic AIRE-expressing cells (eTACs)…
Abstract Number: 0200 • ACR Convergence 2023
Herpes Zoster Prevalence in Patients with Rheumatic Diseases
Rodrigo J. Castillo-de la Garza¹, Jorge A. Esquivel-Valerio², Emmanuel Campos-Tinajero², Anahí Carrazco Chapa³, Gisela García Arellano⁴, Axel A. De Leon-Perez², Pablo Gamez-Siller² and Dionicio A. Galarza-Delgado⁵, ¹Universidad Autónoma de Nuevo León, Monterrey, Mexico, ²Hospital Universitario "Dr. José Eleuterio González", Monterrey, Mexico, ³Facultad de Medicina, Universidad Autónoma de Nuevo León, Monterrey, Mexico, ⁴Hospital Universitario "Dr. José Eleuterio González", Monterrey, Mexico, ⁵Hospital Universitario UANL, Monterrey, Mexico
Background/Purpose: Herpes zoster (HZ) is a painful rash that is commonly known as shingles. People that had a primary infection caused by the varicella-zoster virus…
Abstract Number: 0919 • ACR Convergence 2023
Investigating the Role of Interferon in Promoting Flares of SLE at a Single Cell Level
Zoha Faheem¹, Giselle Boukhaled², Kieran Manion¹, Carolina Munoz-Grajales³, Carol Nassar¹, Michael Kim¹, Dafna Gladman⁴, Murray Urowitz⁵, Zahi Touma⁶, David Brooks² and Joan Wither⁷, ¹Schroeder Arthritis Institute, Krembil Research Institute, Toronto, ON, Canada, ²Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada, ³UHN/TWH, Toronto, ON, Canada, ⁴Schroeder Arthritis Institute, Krembil Research Institute, Toronto Western Hospital, Department of Medicine, University of Toronto, Toronto, ON, Canada, ⁵Schroeder Arthritis Institute, Krembil Research Institute; University of Toronto Lupus Clinic; Division of Rheumatology, Toronto, ON, Canada, ⁶University of Toronto, Toronto, ON, Canada, ⁷University Health Network, Toronto, ON, Canada
Background/Purpose: Systemic lupus erythematosus (SLE) is a heterogeneous autoimmune disease with unpredictable flares interspersed with prolonged periods of disease quiescence. Interferon (IFN) is a hallmark…
Abstract Number: 1689 • ACR Convergence 2023
Deep Cellular Immune Profiling in Psoriatic Arthritis Correlates with Imaging Phenotypes and Response to Targeted Advanced Therapy
Lihi Eder¹, Xianwei Li², Sydney Thib³, Darshini Ganatra⁴, Liqun Diao² and Vinod Chandran⁵, ¹Women’s College Research Institute, Division of Rheumatology, University of Toronto, Toronto, ON, Canada, ²Department of Statistics and Actuarial Science, University of Waterloo, Waterloo, ON, Canada, ³Women’s College Research Institute, Toronto, ON, Canada, ⁴Schroeder Arthritis Institute, Krembil Research Institute, University Health Network, Toronto, ON, Canada, ⁵Schroeder Arthritis Institute, Krembil Research Institute, University Health Network and Division of Rheumatology, Department of Medicine, University of Toronto, Toronto, ON, Canada
Background/Purpose: To characterize the relationships between peripheral blood immune cell profiles in patients with psoriatic arthritis (PsA) and (1) baseline clinical and imaging disease features;…
Abstract Number: 2290 • ACR Convergence 2023
Association of Mycophenolate and Azathioprine Use with Cognitive Function in Systemic Lupus Using a Bayesian Longitudinal Item-response Theory Model
Chrisanna Dobrowolski¹, Juan Pablo Diaz Martinez², Michelle Barraclough³, Roberta Kretzmann⁴, Sherief Marzouk⁴, Kathleen Bingham³, Lesley Ruttan⁵, Dorcas Beaton⁶, Joan Wither³, Carmela Tartaglia⁷, Patti Katz⁸, Mahta Kakvan⁹, Nicole Anderson¹⁰, Dennisse Bonilla³ and Zahi Touma⁴, ¹Icahn School of Medicine at Mount Sinai Hospital, New York, NY, ²Schroeder Arthritis Institute, University Health Network, Toronto, ON, Canada, ³University Health Network, Toronto, ON, Canada, ⁴University of Toronto, Toronto, ON, Canada, ⁵University Health Network, Toronto Rehabilitation Institute, Toronto, ON, Canada, ⁶Institute for Work & Health, Toronto, ON, Canada, ⁷Krembil Brain Institute, University Health Network, University of Toronto, Toronto, ON, Canada, ⁸University of California San Francisco, San Rafael, CA, ⁹University Health Network, University of Toronto, Toronto, ON, Canada, ¹⁰Schroeder Arthritis Institute, Krembil Research Institute, University Health Network and University of Toronto, Toronto, ON, Canada
Background/Purpose: Cognitive dysfunction (CD) is a common and often deleterious manifestation of systemic lupus erythematosus (SLE). CD is usually operationalized on the American College of…
Abstract Number: 0048 • ACR Convergence 2023
Monosodium Urate Crystals Activate an Immune Tolerance Program That Restrains the Activation of Inflammatory Signaling in Macrophages During Gout Flares
Mohnish Alishala¹, Stephen Calderon¹, Anyan Chen¹, Monica Guma², Christopher glass¹ and Isidoro Cobo¹, ¹University of California San Diego, San Diego, CA, ²University of California San Diego, La Jolla, CA
Background/Purpose: Gout is the most frequent form of inflammatory arthritis, with episodes of self-resolving acute inflammation in the joint caused by the deposition of monosodium…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].